Kia ora

  

Thank you for your request for official information. The reference number
for your request is: H2024041059

  

As required under the Official Information Act 1982, Manatū Hauora will
endeavour to respond to your request no later than 20 working days after
the day your request was received. If you'd like to calculate the
timeframe, you can use the Ombudsman's online calculator
here: [1]http://www.ombudsman.parliament.nz/  

  

If you have any queries, please feel free to contact the OIA Services Team
on [2][email address]. If any additional factors come to light which
are relevant to your request, please do not hesitate to contact us so that
these can be taken into account.  

Under section 28(3) of the Act you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [3][email address] or by calling 0800
802 602.

 

Ngā mihi 

 

OIA Services Team 

[4]Ministry of Health information releases 

 

 

------------------- Original Message -------------------
From: ASE <[FOI #26670 email]>; 
Received: Wed May 08 2024 13:47:03 GMT+1200 (New Zealand Standard Time)
To: OIA Requests <[email address]>; OIA <[email address]>; 
Subject: Official Information request - Differences between BNT162b2 and
Comirnaty®

Attn Ministry of Health,

I am seeking information regarding substantive differences between
BNT162b2 and Comirnaty®.

Both products have variously been referred to as “COVID-19 vaccines” and
“vaccine candidates”.

1- Are/were the same manufacturing processes used to manufacture
Comirnaty® and BNT162b2? Has The Ministry of Health confirmed such
information with the manufacturer/supplier?

2- What information is held by The Ministry of Health regarding
similarities and differences between the manufacturing processes of
BNT162b2 and Comirnaty®?

3- Are there any quantifiable differences between BNT162b2 and Comirnaty®,
eg regarding the use or presence of SV40 sequences, the presence of DNA,
the integrity of synthetic mRNA, the use of methyl-pseudouridine, or any
other quantifiable differences?

Thank you,
ASE

 

****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

References

Visible links
1. http://www.ombudsman.parliament.nz/
2. mailto:[email address]
3. mailto:[email address]
4. https://www.health.govt.nz/about-ministr...

hide quoted sections